Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report

Liam James Dwyer; Nimit Singhal; Bing Yu; Steven Kao

doi:10.1016/j.jtho.2024.01.001

Successful Osimertinib Rechallenge After Relapse Following Adjuvant Osimertinib: A Case Report

J Thorac Oncol. 2024 Apr;19(4):650-652. doi: 10.1016/j.jtho.2024.01.001. Epub 2024 Feb 9.

Authors

Liam James Dwyer¹, Nimit Singhal², Bing Yu³, Steven Kao⁴

Affiliations

¹ Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia; Central Clinical School, University of Sydney, Darlington, New South Wales, Australia. Electronic address: liamjames.dwyer@health.nsw.gov.au.
² Cancer Centre, Royal Adelaide Hospital, Adelaide, South Australia, Australia; Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
³ Central Clinical School, University of Sydney, Darlington, New South Wales, Australia; Department of Medical Genomics, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; NSW Health Pathology, Newcastle, New South Wales, Australia.
⁴ Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia; Central Clinical School, University of Sydney, Darlington, New South Wales, Australia.

PMID: 38340108
DOI: 10.1016/j.jtho.2024.01.001

Abstract

Adjuvant osimertinib represents a recent paradigm shift in the management of resected EGFR-mutated lung cancer. The optimal subsequent treatment of patients who relapse after completion of 3 years of adjuvant osimertinib is unknown. Here, we report two cases of complete response to osimertinib rechallenge after relapse from previous adjuvant osimertinib use, and a serial molecular panel exhibiting a lack of acquired resistance mechanisms. Future prospective studies are warranted to confirm the optimal treatment of patients who relapse after previous adjuvant osimertinib.

Keywords: Adjuvant; Case report; NSCLC; Osimertinib; Resistance.

Publication types

Case Reports

MeSH terms

Acrylamides*
Aniline Compounds / pharmacology
Aniline Compounds / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
ErbB Receptors / genetics
Humans
Indoles*
Lung Neoplasms* / drug therapy
Mutation
Protein Kinase Inhibitors
Pyrimidines*
Recurrence

Substances

osimertinib
ErbB Receptors
Aniline Compounds
Protein Kinase Inhibitors
Acrylamides
Indoles
Pyrimidines